# PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

> **NCT05737615** · PHASE1 · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Primary Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Cancer

## Interventions

- **DIAGNOSTIC_TEST:** PET Scan
- **DRUG:** hu5B1-TCO
- **DRUG:** 64Cu-Tz-SarAr
- **DIAGNOSTIC_TEST:** Pharmacokinetics

## Key facts

- **NCT ID:** NCT05737615
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02-10
- **Primary completion:** 2026-02-10
- **Final completion:** 2026-02-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study tracer is currently unavailable
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737615, "PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05737615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*